Reevaluating the senolytic activity of a GLS1 inhibitor and an anti-PD-1 antibody: toward greater reproducibility and methodological rigor.

Shimpei Kawamoto, Haruki Horiguchi, Daisuke Torigoe, Masahiro Wakita, Koyu Ito, Sho Sugawara, Xiangyu Zhou, Takumi Mikawa, Jeong Hoon Park, Birte Kristin Jung, Yumiko Okumura, Hideka Miyagawa, Mikako Maruya, Nozomi Hori, Ken Uemura, Masataka Sugimoto, Michiyuki Matsuda, Naoki Mochizuki, Hiroshi Kondoh, Akiko Takahashi, Yuichi Oike, Eiji Hara

Research Institute for Microbial Diseases, The University of Osaka, Suita, Japan. [email protected] Institute for Microbial Diseases, The University of Osaka, Suita, Japan. [email protected]. · pubmed

Paper

Abstract

The discovery of the senescence-associated secretory phenotype (SASP) has reshaped our understanding of cellular senescence, shifting its role from a solely tumor-suppressive mechanism to a potential driver of chronic inflammation and age-related diseases. Accordingly, senolytic drugs, which selectively eliminate senescent cells, have garnered considerable interest due to promising preclinical studies. However, concerns remain regarding the reproducibility and generalizability of these findings. In this cross-laboratory study, we rigorously tested the senolytic efficacy of a GLS1 inhibitor and an anti-PD-1 antibody-agents previously reported to reduce the burden of p16

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims to rigorously test the senolytic efficacy of a GLS1 inhibitor and an anti-PD-1 antibody. The focus on senolytic drugs and their potential to eliminate senescent cells directly addresses mechanisms of aging and age-related diseases, making it relevant to longevity research.

Author of this paper? Send a correction.